Word of the Day

Commodity

Even if you don't think you do, you already know plenty about commodities. Want us to prove it? No problem.

What makes oil produced in Saudi Arabia different from oil exported from Nigeria? It's the same thing that makes the corn you ate at last summer¿s barbecue different from the corn used to produce ethanol. Stumped? Well, don't feel bad, it's a trick question. The answer? Absolutely nothing. Corn is corn no matter where it comes from -- just as wheat is wheat and natural gas is -- right! -- natural gas. (Though the quality may differ, the make-up is uniform.)

So, in less elaborate terms, corn and oil (and all other commodities) are homogenous goods that can be processed, resold and more often than not, used as an input to the production of other goods or services. These goods are traded on a commodity exchange, thus setting the price-per-barrel (or other metric unit) used to value them.

Now pay attention, here's a question that indeed does have an answer: What is the difference between a commodity and a stock? While a stock can tank and become worthless, a commodity cannot have its value be wiped to zero. One other difference: Most commodities are traded in futures, meaning traders buy and sell where they think the price of a product will be at a certain point in the future. Stocks trade based on the value of the underlying company at that point in time.

Home / Markets / Industries / Health Care

Monday, August 04, 2008

DUSA Pharmaceuticals, Inc. Announces Revised Schedule for Second Quarter Financial Results and Corporate Highlights Conference Call

Email this Story | Respond to Editor | Print

Comtex

WILMINGTON, MASSACHUSETTS, Aug 04, 2008 (MARKET WIRE via COMTEX) ----DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM: DUSA) today announced that it has rescheduled its second quarter earnings release and investor conference call. The second quarter earnings release was previously scheduled to be issued at 6:30am on Tuesday, August 5th with the conference call scheduled for 8:30am. As previously announced on July 18, 2008, the Company was in the process of scheduling a meeting with the FDA regarding the status of Nicomide(R). The meeting with the FDA is now scheduled for August 6th. The revised earnings release date will allow the Company the opportunity to update investors, and our related filings, on the outcome of that meeting.

DUSA now expects that its corporate highlights and second quarter financial results press release will be issued on Friday, August 8th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

   Friday, August 8th - 8:30 a.m. Eastern If calling from the US or Canada use the following toll-free number: 800.647.4314 Password
   - DUSA For International callers use 435.871.6103 A recorded replay of the call will be available North American callers 877.863.0350
   International callers 858.244.1268

The call will be accessible on our web site approximately one hour following the call at www.dusapharma.com.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach(TM) and Nicomide(R). DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, Mass. Please visit the company's website at www.dusapharma.com for more information.

 Contacts:
   DUSA Pharmaceuticals, Inc. Shari Lovell Director, Shareholder Services (978) 657-7500 Ext. 1121 Website: www.dusapharma.com

SOURCE: DUSA Pharmaceuticals, Inc.

http://www.dusapharma.com

Copyright 2008 Market Wire, All
   rights reserved. ********************************************************************** As of Thursday, 07-31-2008 23:59,
   the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a DOWNTREND on 07-14-2008 for DUSA
   @ $1.91. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a
   registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.